Arcturus Therapeutics Holdings Inc. (ARCT) Financial Statements (2026 and earlier)

Company Profile

Business Address 10285 SCIENCE CENTER DRIVE
SAN DIEGO, CA
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments230,909237,028292,005391,883370,492462,895
Cash and cash equivalent230,909237,028292,005391,883370,492462,895
Restricted cash and investments  55,00055,000   
Receivables5,5643,97432,0642,7643,3672,125
Other undisclosed current assets4,9739,9777,5218,6865,1022,769
Total current assets:241,446305,979386,590403,333378,961467,789
Noncurrent Assets
Operating lease, right-of-use asset21,08126,67428,50032,5455,6185,182
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization6,7369,53112,42712,4155,6433,378
Long-term investments and receivables     515 
Long-term investments     515 
Restricted cash and investments1,8851,8851,8852,0942,077107
Total noncurrent assets:29,70238,09042,81247,05413,8538,667
TOTAL ASSETS:271,148344,069429,402450,387392,814476,456
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28,13345,97537,16037,68133,58131,413
Accounts payable4,2357,1945,2797,44910,05810,774
Accrued liabilities23,89838,78131,88130,23223,52320,639
Deferred revenue8,24619,51444,82928,64843,48218,108
Debt    60,65522,474 
Total current liabilities:36,37965,48981,989126,98499,53749,521
Noncurrent Liabilities
Long-term debt and lease obligation     45,13517,870
Long-term debt, excluding current maturities     40,63313,845
Liabilities, other than long-term debt20,78437,60268,90053,09119,93112,512
Deferred revenue  12,60442,49620,07119,93112,512
Other liabilities   4972,804  
Operating lease, liability20,78424,99825,90730,2164,5024,025
Total noncurrent liabilities:20,78437,60268,90053,09165,06630,382
Total liabilities:57,163103,091150,889180,075164,60379,903
Equity
Equity, attributable to parent213,985240,978278,513270,312228,211396,553
Common stock282727272626
Additional paid in capital728,547689,758646,352608,426575,675540,343
Accumulated deficit(514,590)(448,807)(367,866)(338,141)(347,490)(143,816)
Total equity:213,985240,978278,513270,312228,211396,553
TOTAL LIABILITIES AND EQUITY:271,148344,069429,402450,387392,814476,456

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues82,031152,310166,799205,99912,3599,539
Gross profit:82,031152,310166,799205,99912,3599,539
Operating expenses(158,291)(247,979)(245,004)(193,822)(215,211)(81,063)
Operating income (loss):(76,260)(95,669)(78,205)12,177(202,852)(71,524)
Nonoperating income (expense)10,47714,72416,362(1,018)(1,337)(361)
Gain (loss), foreign currency transaction, before tax382(471)(229)(598)584 
Other nonoperating income (expense)10,09515,19516,591(420)(1,921)(361)
Interest and debt expense   33,953(900)(2,700)(900)
Other undisclosed income from continuing operations before equity method investments, income taxes  161,995    
Income (loss) from continuing operations before equity method investments, income taxes:(65,783)81,050(27,890)10,259(206,889)(72,785)
Income (loss) from equity method investments    (515)515(263)
Other undisclosed income (loss) from continuing operations before income taxes  (161,995) 900  
Income (loss) from continuing operations before income taxes:(65,783)(80,945)(27,890)10,644(206,374)(73,048)
Income tax expense (benefit) 4(1,835)(1,295)  
Other undisclosed income from continuing operations      
Income (loss) from continuing operations:(65,783)(80,941)(29,725)9,349(206,374)(73,048)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(206,374)(73,048)
Net income (loss):(65,783)(80,941)(29,725)9,349(206,374)(73,048)
Other undisclosed net income attributable to parent    2,700900
Net income (loss) available to common stockholders, diluted:(65,783)(80,941)(29,725)9,349(203,674)(72,148)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(65,783)(80,941)(29,725)9,349(206,374)(73,048)
Comprehensive income (loss):(65,783)(80,941)(29,725)9,349(206,374)(73,048)
Other undisclosed comprehensive income, net of tax, attributable to parent    2,700900
Comprehensive income (loss), net of tax, attributable to parent:(65,783)(80,941)(29,725)9,349(203,674)(72,148)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: